Avian influenza (H5N1) vaccine to prevent infection, first in Korea to enter clinical trials.

[Sally Furniss]

avian influenza (H5N1) vaccine to prevent infection, first in Korea to enter clinical trials.

Food and Drug Administration, Center for Disease Control of the Green Cross is receiving services under development, clinical trials for bird flu vaccine MG1109 enforcement has been approved by 12 days.

Clinical trials with the vaccine immune jeunggangje otherwise be put to compare the two ancient forms Guro Hospital, 1 years 5 months at the next 292 people who will be implemented.

The vaccine to enter clinical trials for bird flu epidemic in preparation to create 'a model vaccine, next to the bird flu during the epidemic, the antigens in a manner that will be used to replace Drain.

The current worldwide bird flu vaccine, hooked up a model where Novartis of Switzerland, and France's Sanofi Pasteur has a multi-national companies baeksineopche 8.

FDA on the same day of the Green Cross Green flu swine flu vaccine - Estonia's infant target additional clinical trial has been approved. The study of 6 months to 3 years old infants will be conducted by 63 people.

http://www.asiae.co.kr/news/view.htm?sec=eco3&idxno=2009111210020423080

[gsgs]

Re: Avian influenza (H5N1) vaccine to prevent infection, first in Korea to enter clinical trials.

I don't understand this, does it say what the headline
seems to announce ?

They are testing how well the vaccine works ?

(vaccinate one community and not another one - compare
#infections)

[Sally Furniss]

Re: Avian influenza (H5N1) vaccine to prevent infection, first in Korea to enter clinical trials.

From KFDA
Korean Food and drug Administration

- (Shares) of Green Cross' Pre-epidemic influenza (H5N1) vaccine clinical trial approved --

□ Korea to establish the sovereignty of the bio-clinical trial was approved to contribute.

□ Food and Drug Administration (Administration yunyeopyo) the (Day) is being developed by Green Cross of bird flu (H5N1) vaccine (MG1109) for the first time in Korea has approved a clinical trial.
○ The vaccine (primary), Green Cross Center for Disease Control has received the services of a development started in earnest since 2007 been the toxicity, the effect of testing across a variety of animal testing and clinical trials have been prepared, inert qualified jeonbayireoseu 1) antigen jeunggangje immune to the 'alrum (alum) '2) vaccine is used.
○ Phase 1 clinical trial (phase 1) in two stages when little or no response (Phase 2) continue to be used as a form of immune jeunggangje formulation and dosage form is not used to compare the two vaccines will be tested and
Ancient ○ Guro Hospital at 17 months the number of subjects in clinical trials are in progress step-by healthy adults, 40 of each name is 252 people.

The vaccine is FDA □ bird flu epidemic begins to be used in all phases has been developed
○ future bird flu epidemic when a virus vaccines create real fashion can be used as a model country to respond to the disease itself was equipped with the system means that claimed he took the first step, he said.
○ Note that for the meantime in case of epidemic influenza vaccine model, Novartis, Sanofi-Pasteur and the development of multinational companies and Europe at baeksineopche 8 has permissions.

"Glossary"
1) bulhwalhwa jeonbayireoseu (Inactivated Whole virus) vaccine: an inert form of split virus vaccine and, typically split virus, split (split) compared to the vaccine induced a high immune castle won one of the local injection site reactions high known
2) alrum (alum): aluminum components to generate antibodies in the immune jeunggangje to increase jujakyongim

http://www.kfda.go.kr/index.kfda?mid=56&page=safeinfo&mmid=327&seq=10632